ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

リコンビナントタンパク質

ACROBiosystems社 プロダクトリスト:Recombinant Protein

サプライヤー
AcroBioSystems
カタログNo.
CA9-S5149
製品名称
GENPower? NLS-Cas9 Nuclease, premium grade
タンパク質名
CAS9
Species
Streptococcus pyogenes
HOST
E. coli
250ug: 128800円
お問い合わせ
20ug: 84000円
お問い合わせ
100ug: 218400円
お問い合わせ

Overview

Synonyms -
Characteristics N/A
Endotoxin Level 0.01 EU per μg
Purity 95%
Description CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids),CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and this protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA; Cas9 only stabilizes the pre-crRNA:tracrRNA interaction and has no catalytic function in RNA processing. Subsequently Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer; Cas9 is inactive in the absence of the 2 guide RNAs (gRNA). The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. DNA-binding requires protein and both gRNAs, as does nuclease activity. Cas9 recognizes the protospacer adjacent motif (PAM) in the CRISPR repeat sequences to help distinguish self versus nonself, as targets within the bacterial CRISPR locus do not have PAMs. DNA strand separation and heteroduplex formation starts at PAM sites; PAM recognition is required for catalytic activity.
Reference -
URL https://www.acrobiosystems.com/P4819-GENPower%E2%84%A2-NLS-Cas9-Nuclease-%28MALS-verified%29.html

お問い合わせリスト(-)

お問い合わせフォーム